Innovation in Healthcare and Pharma
Oliba helps healthcare organizations to bridge the technological gap that still prevents individuals, patients, caregivers, and professionals to embrace sustainable innovation, safeguard wellness, and increased empowerment for making appropriate health decisions.
Innovation is reshaping the way healthcare services are provided and utilized; disruptive technologies (including advanced therapies, digital innovations, wearable technologies, machine learning, artificial intelligence) are changing patient perceptions with the aim to tailor care process around the individual’s needs.
Innovations in healthcare and the pharma industry can enable breakthrough performance to generate more value, better outcomes, greater convenience, access and, ultimately, cost-efficiency. However, complexities of implementation, accessibility, and acceptance are often barriers to diffusion.
Oliba can help you to find a way to integrate the right technology to boost and enhance process into your organization including (but not limited to):
- Next-generation sequencing: applications of genetic sequencing to identify at-risk populations or target therapies to patients who are likely to respond.
- Advanced therapies: new medical products that use gene therapy, cell therapy, and tissue engineering to treat diseases or injuries.
- Artificial intelligence: the ability of computers to think like and complete tasks currently performed by humans with greater speed, accuracy, and lower resource utilization.
- Point-of-care diagnostics: allow for convenient, timely testing at the point of care (e.g., physician office, ambulance, home, or hospital), resulting in faster, more cohesive patient care.
- Leveraging digital tools to improve patient experience: tapping data from social media and online communities to give healthcare organizations the ability to track consumer experience and population health trends in real-time.
- Biosensors and trackers: technology-enabled activity trackers, monitors, and sensors incorporated into clothing, accessories, and devices that allow consumers and clinicians to easily monitor health.
- Telemedicine and Telehealth: a more convenient way for consumers to access and increase self-care while potentially reducing office visits and travel time, which may also prevent complications and reduce emergency room visits.
Leveraging the Health Ecosystem
Oliba operates at the center of a multitude of stakeholders (patient and caregiver associations, pharmaceutical companies, institutions, and regulators) facilitating relationships, interactions, and knowledge exchange. We embrace the process of converging healthcare sectors through mergers, partnerships, affiliations, and collaborations as many stakeholders seek to eliminate redundancies, improve fixed-asset efficiencies, match costs to patients’ clinical needs more effectively, and align incentives across industry sectors. Ultimately, this can help to improve individuals’ health, wellbeing, and quality of life by enabling easier access to quality healthcare services.
Digitalization of Healthcare Data
Oliba can successfully integrate digital technologies into your organization’s processes, for instance through a progressive adoption of Electronic Health Records. Many institutions in the private and public sector have already moved to the third wave of IT adoption— including full digitization of their entire enterprise, comprising digital products, channels, and processes, as well as advanced analytics. These transitions have generated more effective operating models and a safer management of care procedures. From a patient perspective non-digital channels will continue to be relevant, so digital channels will have to be embedded in a well-thought-through multichannel concept. Data shows that more than 75 percent of respondents would like to use digital healthcare services, as long as those services meet their needs and provide the level of quality they expect. We are working towards a digitalization process that could be a triple win for the patient, the payor, and the healthcare industry in a process of value co-generation.
A new generation of therapeutic and diagnostic technologies is making its way from research settings to clinical practice. They represent an ongoing transformation where manufacturers, regulators, and care providers must address a number of topics to live up to expectations, including clinical, regulatory, and market access hurdles, which have broader implications for health systems as a whole in terms of social and economic sustainability.
Looking broadly across the healthcare industry, there are five major forces at play that will likely shape the future of therapies:
- Smaller patient populations due to narrower stratification of subpopulations in more common tumour types.
- Shorter product life cycles, which have reduced by almost fivefold since the 1990s because of a more competitive landscape and faster innovation cycles.
- A new age of combination therapy and sources of innovation triggered by an increased level of external sourcing of innovation and collaboration especially among pharmaceutical and biotechnology companies.
- A significant shift in value across healthcare, partly driven and informed by big data, which in turn will enable more innovative access models.
- A new wave of medical technologies, providing tools to address a broader set of indications and offering a greater promise of personalized therapies.
Oliba can provide you with a comprehensive perspective on the clinical, regulatory, organizational, and financial impacts of the introduction of advanced therapies even before marketing authorization. We can also devise strategic programs to market innovative therapeutic and diagnostic technologies in certain settings (commercial strategy design and implementation, sales forecasting, institutional relationship with national or local authorities, communication and/or education campaigns etc).